

AMENDMENTS TO THE CLAIMS

Please cancel claims 1-6, 8-16, 19, 20, 24-27, 34, 35, 80, 83 and 84; amend claims 7, 17, 18, 21-23, 28-33 and 36; and add new claims 85-89, as shown in the following listing of claims:

1.-6. (Canceled).

7. (Currently Amended) A method in accordance with claim 85, wherein said W Ar² is ~~a substituted or unsubstituted phenyl or a substituted or unsubstituted naphthyl~~.

8.-16. (Canceled).

17. (Currently Amended) A method in accordance with claim 85 14, wherein said ~~CCR4-~~mediated condition or disease is atopic dermatitis.

18. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-~~mediated condition or disease is asthma ~~a disease of the airway~~.

19.-20. (Canceled).

21. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-~~mediated condition or disease is rheumatoid arthritis ~~a disease of innate immunity~~.

22. (Currently Amended) A method in accordance with claim 85 21, wherein said ~~condition or disease of innate immunity~~ is multiple sclerosis ~~septic shock~~.

23. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-~~mediated condition or disease is atherosclerosis.

24.-27. (Canceled).

28. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-~~mediated disease or condition is atopic dermatitis and said compound is used alone or in combination with at least one therapeutic agent selected from a lubricant and corticosteroid.

29. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-mediated~~ condition or disease is asthma and said compound is used alone or in combination with at least one therapeutic agent selected from a β 2-agonist and a corticosteroid.

30. (Currently Amended) A method in accordance with claim 85 1, wherein said compound interferes with the interaction between CCR4 and a ligand.

31. (Currently Amended) A method in accordance with claim 85 1, wherein said administration is oral or intravenous.

32. (Currently Amended) A method in accordance with claim 85 1, wherein said subject is selected from the group consisting of human, rat, dog, cow, horse, and mouse.


33. (Currently Amended) A method in accordance with claim 85 1, wherein said subject is human.

34.-35. (Canceled).

36. (Currently Amended) A method in accordance with claim 85 1, wherein said ~~CCR4-mediated~~ disease or condition is ~~selected from the group consisting of multiple sclerosis, rheumatoid arthritis, type I diabetes, psoriasis, cancer and HIV infection.~~ ; ~~Ar¹ is a substituted heterocycle; X is NH ; and Ar² is naphthyl.~~

37.-84. (Canceled).

85. (New) A method for treating a disease or condition selected from asthma, atopic dermatitis, atherosclerosis, multiple sclerosis, rheumatoid arthritis and HIV infection in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I):



or a pharmaceutically acceptable salt thereof, wherein

W is naphthyl;


X is S;

Y is NH;


Z is N;

R^1 and R^2 are independently selected from H, halogen, CN, CO_2R' , $CONR'R''$ and (C_1-C_8) alkyl, wherein R' and R'' are independently selected from H, (C_1-C_8) alkyl and aryl, and when R' and R'' are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.


86. (New) A method in accordance with claim **85**, wherein said compound is




87. (New) A method in accordance with claim **85**, wherein said compound is



88. (New) A method in accordance with claim **85**, wherein said compound is selected from the group consisting of:





89. (New) A method in accordance with claim **85**, wherein said compound is

